SURENA MATIN to Bone Neoplasms
This is a "connection" page, showing publications SURENA MATIN has written about Bone Neoplasms.
Connection Strength
0.197
-
Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960.
Score: 0.072
-
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
Score: 0.057
-
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
Score: 0.052
-
External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World J Urol. 2018 Dec; 36(12):1973-1980.
Score: 0.016